Ovagen — Khavinson bioregulator — liver / gastrointestinal (CRITICAL: zero published human trials)
Ovagen (Glu-Asp-Leu) is marketed as a liver and gastrointestinal bioregulator. The EDL tripeptide does show bioactivity in vitro (HIV protease inhibition confirmed). HOWEVER: ZERO published peer-reviewed human clinical trials exist for Ovagen's marketed liver/GI/ovarian effects. All promotional claims cite an unverifiable '106-patient study' with no journal citation, author list, or accessible publication. PubMed search returns zero results for Ovagen human studies.
Overview
This page is part of Hormonaly's evidence-graded compound library. All clinical claims are linked to peer-reviewed sources via our dual-layer citation verification pipeline.
Compound Class
Khavinson bioregulator — liver / gastrointestinal (CRITICAL: zero published human trials)
Mechanism of Action
Ovagen (Glu-Asp-Leu) is marketed as a liver and gastrointestinal bioregulator. The EDL tripeptide does show bioactivity in vitro (HIV protease inhibition confirmed). HOWEVER: ZERO published peer-reviewed human clinical trials exist for Ovagen's marketed liver/GI/ovarian effects. All promotional claims cite an unverifiable '106-patient study' with no journal citation, author list, or accessible publication. PubMed search returns zero results for Ovagen human studies.
Regulatory Status
Not FDA approved. Supplement/research peptide. High conflict of interest: developed and sold by the same institution (Institute of Bioregulation and Gerontology).
Evidence Level
INSUFFICIENT — Zero published peer-reviewed human clinical trials. In vitro EDL tripeptide bioactivity confirmed but no human data for marketed indications. Evidence score: 1/5.